KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Change in Inventory (2021 - 2025)

Historic Change in Inventory for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Q3 2025 value amounting to -$1.7 million.

  • Aurinia Pharmaceuticals' Change in Inventory fell 113021.58% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year increase of 313.88%. This contributed to the annual value of -$477000.0 for FY2024, which is 10300.59% down from last year.
  • According to the latest figures from Q3 2025, Aurinia Pharmaceuticals' Change in Inventory is -$1.7 million, which was down 113021.58% from $308000.0 recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Change in Inventory's 5-year high stood at $7.0 million during Q1 2023, with a 5-year trough of -$1.7 million in Q3 2025.
  • In the last 5 years, Aurinia Pharmaceuticals' Change in Inventory had a median value of $614000.0 in 2022 and averaged $1.9 million.
  • Examining YoY changes over the last 5 years, Aurinia Pharmaceuticals' Change in Inventory showed a top increase of 1234107.14% in 2025 and a maximum decrease of 113021.58% in 2025.
  • Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Change in Inventory stood at $278000.0 in 2021, then surged by 120.86% to $614000.0 in 2022, then surged by 1021.34% to $6.9 million in 2023, then crashed by 92.53% to $514000.0 in 2024, then plummeted by 432.68% to -$1.7 million in 2025.
  • Its Change in Inventory stands at -$1.7 million for Q3 2025, versus $308000.0 for Q2 2025 and $7.0 million for Q1 2025.